Literature DB >> 33471127

Patients and Clinicians Define Symptom Levels and Meaningful Change for PROMIS Pain Interference and Fatigue in RA using Bookmarking.

Clifton O Bingham1, Alessandra L Butanis1, Ana Maria Orbai1, Michelle Jones1, Victoria Ruffing1, Anne Lyddiatt2, Mary Suzanne Schrandt3, Vivian P Bykerk4, Karon F Cook5, Susan J Bartlett1,6,7.   

Abstract

OBJECTIVES: Using patient-reported outcomes (PROs) to inform clinical decision-making depends on knowing how to interpret scores. Patient-Reported Outcome Measurement Information System® (PROMIS®) instruments are increasingly used in rheumatology research and care, but there is little available to guide interpretation of scores. We sought to identify thresholds and meaningful change for PROMIS Pain Interference and Fatigue scores from the perspective of rheumatoid arthritis (RA) patients and clinicians.
METHODS: We developed patient vignettes using the PROMIS item banks representing a continuum of Pain Interference and Fatigue levels. During a series of face-to-face "bookmarking" sessions, patients and clinicians identified thresholds for mild, moderate, and severe levels of symptoms and identified change deemed meaningful for making treatment decisions.
RESULTS: In general, patients selected higher cut points to demarcate thresholds than clinicians. Patients and clinicians generally identified changes of 5-10 points as representing meaningful change. The thresholds and meaningful change scores of patients were grounded in their lived experiences having RA, approach to self-management, and the impacts on function, roles, and social participation.
CONCLUSION: Results offer new information about how both patients and clinicians view RA symptoms and functional impacts. Results suggest that patients and providers may use different strategies to define and interpret RA symptoms, and select different thresholds when describing symptoms as mild, moderate or severe. The magnitude of symptom change selected by patients and clinicians as being clinically meaningful in interpreting treatment efficacy and loss of response may be greater than levels determined by external anchor and statistical methods.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PROMIS; Patient reported outcomes; Patient reported outcomes measurement information system

Year:  2021        PMID: 33471127     DOI: 10.1093/rheumatology/keab014

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

1.  Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.

Authors:  Ana-Maria Orbai; Laura C Coates; Atul Deodhar; Philip S Helliwell; Christopher T Ritchlin; Evan Leibowitz; Alexa P Kollmeier; Elizabeth C Hsia; Xie L Xu; Shihong Sheng; Yusang Jiang; Yan Liu; Chenglong Han
Journal:  Patient       Date:  2022-06-30       Impact factor: 3.481

2.  Functional and psychosocial impact of COVID-19 pandemic on rheumatic patients' quality of life in Saudi Arabia.

Authors:  Lena M Hassen; Rana A Albarrak; Reem A Albahlal; Dimah K Alsaqabi; Ikhlass M Hassen; Maha H Daghestani; Eman M Alqurtas; Abdulaziz T Alkhalaf; Mohammed K Bedaiwi; Mohammed A Omair; Ibrahim A Almaghlouth
Journal:  Qual Life Res       Date:  2022-07-20       Impact factor: 3.440

Review 3.  Mitochondrial Dysfunction in Rheumatoid Arthritis.

Authors:  Chen Ma; Jie Wang; Fenfang Hong; Shulong Yang
Journal:  Biomolecules       Date:  2022-09-01

Review 4.  Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures.

Authors:  Caroline B Terwee; John Devin Peipert; Robert Chapman; Jin-Shei Lai; Berend Terluin; David Cella; Philip Griffith; Lidwine B Mokkink
Journal:  Qual Life Res       Date:  2021-07-10       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.